View Older Stories View More Recent Stories
-
Morgan Stanley Reiterates Equalweight Rating on Gilead Sciences (GILD)
-
BMO Capital Gilead Sciences (GILD) at Outperform following latest HIV data
-
Gilead's (GILD) Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada
-
Piper Sandler Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) and Genesis Therapeutics Enter Strategic Collaboration to Discover and Develop Novel Therapies
-
Gilead Sciences (GILD) to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer
-
Gilead Sciences (GILD) PT Raised to $74 at RBC Capital
-
TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD)
-
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) PT Raised to $83 at Truist Securities
-
Gilead Sciences' (GILD) Livdelzi Granted Accelerated FDA Approval for Primary Biliary Cholangitis
-
Gilead's (GILD) Livdelzi Approved by FDA for Primary Biliary Cholangitis
-
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
-
Gilead Sciences (GILD) PT Raised to $85 at BMO Capital
-
Gilead Sciences (GILD) PT Raised to $72 at RBC Capital
-
Stocks expected to have increasing option volume: GILD TTD TTWO EXPE AKAM PODD ELF DBX PARA
-
Gilead Sciences (GILD) Tops Q2 EPS by 41c; offers guidance
-
Gilead Sciences (GILD) option IV elevated, call put ratio 1 call to 1.1 puts into quarte reuslts
-
Gilead Sciences (GILD) August 9 weekly 74 straddle priced into quarter results
-
Gilead Sciences (GILD) Presents Research Data Across Its Broad
-
TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) Announces Upcoming Departure of Chief Medical Officer
-
Raymond James Upgrades Gilead Sciences (GILD) to Outperform
-
Gilead Sciences (GILD) option IV flat into 2024 USA elections
-
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
-
Increasing unusual option volume: PPL SWBI SARK SRPT CNK NVD MTN EWT FFIE PCT GILD
-
Gilead Sciences (GILD) option IV amid rally
-
Gilead Sciences (GILD) call put ratio 3.8 calls to 1 put as share price up 8%
-
Gilead Sciences (GILD) jumps on Lenacapavir data
-
RBC Capital on Gilead Sciences (GILD): 'stock getting closer to what we view as fair value'
-
BMO Capital on Gilead Sciences (GILD): 'If positive, PURPOSE-2 could allow for an approval of lenacapavir as early as late 2025'
-
Baird on Gilead Sciences (GILD): 'Incrementally positive on clinical data'
-
Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada for HIV Prevention
-
Gilead Sciences (GILD) GS-4571 Intended for NASH Not Obesity - Mizuho
-
Gilead Sciences (GILD) call put ratio 3.6 calls to 1 put amid price movement
-
Midday movers: Adobe, Hasbro rise; GameStop and RH fall
-
Evercore ISI on Gilead (GILD): 'Gilead isn’t hyping it etc, the conversation flow was us reaching out to Gilead to clarify, rather than Gilead flagging it to everyone'
-
Gilead Sciences (GILD) Trades at High, Up 4.3%
-
Gilead Sciences (GILD) call put ratio 7.3 calls to 1 put with focus on June weekly (14) 64 calls.
-
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
